• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tunable hydrogel helps predict tissue response to chemotherapy

October 12, 2016 By Sarah Faulkner

Tunable polymersResearchers from the Wyss Institute developed a hydrogel microenvironment to evaluate how physical properties like stiffness of the extracellular matrix impacts the efficacy of chemotherapy.

“To have success with chemotherapy and other drug therapies, we will likely need to screen their effectiveness against cells living in various environments, and not just assume that cells will always respond to a drug the same way that they would in conventional cell culture,” senior author David Mooney said in prepared remarks.

The study, published yesterday in Proceedings of the National Academy of Sciences, describes a drug screen assay using alginate hydrogels that were tuned to recapitulate stiffness and other properties characteristic of tumors and healthy tissue. Cancer cells were loaded into the hydrogel and bombarded with chemotherapy, according to the study, and researchers evaluated the drug’s efficacy based on the level of resistance the cells build up.

They found that even when they tested the hydrogel in mice, a softer extracellular matrix accelerated cancer growth and led to more cellular resistance to the chemotherapy.

“We envision that our 3D hydrogels could bridge the gap between in vitro drug screening and in vivo pre-clinical studies,” Jae-Won Shin, assistant professor at the University of Illinois at Chicago, added.

“It is crucial that we consider the importance of the local tissue microenvironment when designing new cancer therapies, as we now understand that mechanics is as important as biochemistry,” founding director Dr. Donald Ingber said. “These engineered 3D hydrogels, which enable investigators to mimic the mechanical environment of cancers in different organs, also potentially offer a new approach to developing precision medicine therapies being that could be tailored to patient-specific tumor environments.”

Filed Under: Featured, Oncology, Pharmaceuticals, Research & Development Tagged With: Wyss Institute

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS